Therefore, a series of drugs targeting the VHL-HIF2α-VEGFA axis in RCC were investigated and developed, like PT2399, VEGFA inhibitor, or sunitinib [9, 10]. This evidence concerns the gene EPAS1 and renal cell carcinoma.